Clinical Trials
Below are current clinical trials.
265 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to understand when patients are shedding active COVID virus RNA as detectable by viral culture, and if there are any correlates of the cessation of active viral shedding, such as presence of certain immunoglobulins.
Additionally, this study will take a discovery approach to the immune response to better understand how the body recovers or worsens during disease, and if there are opportunities to use that knowledge to develop treatments.
-
Scottsdale/Phoenix, Ariz.
The primary purpose of this study is to assess the safety of clazakizumab treatment in COVID-19 infected patients with respiratory failure due to hyperinflammation related to cytokine storm.
-
Jacksonville, Fla.
The purpose of this study is to evaluate the safety and tolerability of PC945 for the prevention of fungal aspergillus infections in the lung in patients who have received a lung transplant.
-
Rochester, Minn.
The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
-
Rochester, Minn.
The purpose of this study is to remotely use the Ellipsis Health (EH) voice analysis technology to record the speech patterns and content of individuals with a recent diagnosis of Coronavirus-19 (COVID-19) presenting to the post-COVID-19 clinic at Mayo Clinic, to validate its use as a tool to screen for major depressive disorder (MDD) and generalized anxiety disorder (GAD) against gold-standard questionnaires used in clinical practice namely the PHQ-9 and GAD-7
-
Rochester, Minn.
The primary purpose of this study is to estimate the incidence rate of confirmed respiratory syncytial virus (RSV) (and other confirmed respiratory viruses) infections and associated adverse outcomes.
-
Jacksonville, Fla.
Stage A: To evaluate the safety and efficacy of the INTERCEPT Blood System for Red Blood Cells Pathogen Reduction Treatment (PRT) in comparison to conventional RBCs in adult patients who require RBC transfusion support. Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been infected or is at risk of infection by the Zika virus (ZIKV), and the risk of asymptomatic infection among qualified blood donors is recognized. Besides the reduction of risk of transfusion transmitted ZIKV, the intent of the study is also to reduce the risk of transfusion-transmitted infections (TTI) in general, including transfusion related sepsis and other emerging or concurrent endemic pathogens (e.g. Dengue and Chikungunya), and to reduce the risk of TA-GVHD. As part of this treatment use study, additional data will be provided on the safety of INTERCEPT-treated RBCs (IBS RBCs) supplied for routine clinical transfusion practice.
-
Jacksonville, Fla.
The purpose of this study is to evaluate Lamprene (Clofazimine) to treat non-tuberculous mycobacterial (NTM) infections.
-
Rochester, Minn.
We purpose of this study is to evaluate the diagnosis accuracy of the Controlled Attenuation Parameter (CAP) measured by FibroScan® (both with M and XL probes) in all patients who are undergoing liver biopsy for any liver disease.
-
Rochester, Minn.
The purpose of this study is to explore lay understandings toward participating in and perceptions of consent to biospecimen research and valuation of genetics in SARS-COV-2 infection, testing, immunity, and vaccine development, to explore professional attitudes toward and perception of barriers and facilitators for implementating genetic technology to facilitate understanding of SARS-COV-2 infection and immunity, improvement and scale-up of testing, and vaccine development, and to identify ethical, social, and inter-professional aspects of microbial genetic technology implementation in population health surveillance, clinical test development, and vaccine research.We hypothesize that engagement with individuals whom directly experience and/or are impacted by the increasing use of SARS-Cov-2 genetic technology, including COVID-19 Pandemic Response Biobank contributors and interdisciplinary expert teams will help identify ethical and social issues in adopting and implementing emerging technology.